Unknown

Dataset Information

0

Prominin-1 (CD133, AC133) and dipeptidyl-peptidase IV (CD26) are indicators of infinitive growth in colon cancer cells.


ABSTRACT: Advanced colorectal cancer is characterized by uncontrolled growth and resistance against anti-cancer agents, including ErbB inhibitors. Recent data suggest that cancer stem cells (CSC) are particularly resistant. These cells may reside within a CD133+ fraction of the malignant cells. Using HCT116 cells we explored the role of CD133 and other CSC markers in drug resistance in colon cancer cells. CD133+ cells outnumbered CD133- cells over time in long-term culture. Both populations displayed the KRAS mutation 38G > A and an almost identical target profile, including EGFR/ErbB1, ErbB2, and ErbB4. Microarray analyses and flow cytometry identified CD26 as additional CSC marker co-expressed on CD133+ cells. However, knock-down of CD133 or CD26 did not affect short-term growth of HCT116 cells, and both cell-populations were equally resistant to various targeted drugs except irreversible ErbB inhibitors, which blocked growth and ERK1/2 phosphorylation in CD133- cells more efficiently than in CD133+ cells. Moreover, the MEK inhibitor AS703026 was found to overcome resistance against ErbB blockers in CD133+ cells. Together, CD133 and CD26 are markers of long-term growth and resistance to ErbB blockers in HCT116 cells, which may be mediated by constitutive ERK activity.

SUBMITTER: Grunt TW 

PROVIDER: S-EPMC4396035 | biostudies-literature | 2015

REPOSITORIES: biostudies-literature

Similar Datasets

2011-12-31 | E-MTAB-583 | biostudies-arrayexpress
| S-EPMC154298 | biostudies-literature
| S-EPMC2876037 | biostudies-literature
| S-EPMC2193361 | biostudies-literature
| S-EPMC3689814 | biostudies-literature
| S-ECPF-MTAB-583 | biostudies-other
| S-EPMC5536003 | biostudies-literature
| S-EPMC7063094 | biostudies-literature
| S-EPMC3636202 | biostudies-literature
| S-EPMC2747550 | biostudies-other